Additionally, increased NOX4 levels due to hypertrophic stimuli, such as angiotensin II, can further induce HDAC4 nuclear export, which plays a critical role in the suppression of cardiac hypertrophy [30], while DPP4 inhibitor teneligliptin was revealed to decrease cardiac hypertrophy via inhibition of NOX4 mRNA increase and HDAC4 export by increasing GLP1 levels [30]. Here, DPP4 is linked to cardiac hypertrophy.